Filing Flows › Beam Therapeutics (BEAM) › Stock forecast & fair value
Beam Therapeutics (BEAM) stock forecast and price target
Beam Therapeutics (BEAM) trades at $26.41. 13 analysts' median price target is $45.00 (+70%), from $26.00 to $80.00.
Beam Therapeutics' latest quarter
Beam Therapeutics, Q3 2026: revenue $307K (-97% year over year), net loss $134M, operating cash flow −$111M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for BEAM stock?
The median of 13 analysts' 12-month targets is $45.00, +70% from $26.41; the range is $26.00 to $80.00. The average rating is strong buy.
Does Beam Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 40% of the quarters on record.
Is BEAM stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.